Adage Capital Partners’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Adage Capital Partners’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-125,000	Closed	-$305K	–	813
2020 Q1	$305K	Hold	125,000	–	–	﹤0.01%	711
2019 Q4	$640K	Hold	125,000	–	–	﹤0.01%	690
2019 Q3	$808K	Hold	125,000	–	–	﹤0.01%	690
2019 Q2	$779K	Hold	125,000	–	–	﹤0.01%	686
2019 Q1	$1.33M	Hold	125,000	–	–	﹤0.01%	656
2018 Q4	$996K	Hold	125,000	–	–	﹤0.01%	682
2018 Q3	$2.42M	Hold	125,000	–	–	0.01%	669
2018 Q2	$2.26M	Buy	+125,000	New	+$1.84M	0.01%	690

Other funds holding SIOX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners's SIOX Position: Q2 2020 in Review

Adage Capital Partners sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2020, closing a stake of 125,000 shares — an estimated $305K sold.

Adage Capital Partners first reported a position in SIOX in Q2 2018 and held it in 8 quarters. The position peaked at $2.42M in Q3 2018. 40 funds tracked by Wall St. Rank hold SIOX as of Q2 2020.

Adage Capital Partners reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Adage Capital Partners sold 125,000 Sio Gene Therapies Inc. Common Stock shares in Q2 2020, an estimated $305K.
Adage Capital Partners first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2018 and held it in 8 quarters.
Adage Capital Partners's Sio Gene Therapies Inc. Common Stock position peaked at $2.42M in Q3 2018.
40 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2020.

Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.